FASLG polymorphism is associated with cancer risk

European Journal of Cancer

Volumn 45, Issue 14, 2009, Pages 2574-2578

  Liu, Yan ^a   Wen, Qian Jun ^b   Yin, You ^c   Lu, Xiao Tong ^a   Pu, Shu Hong ^a   Tian, Huai Ping ^a   Lou, Yue Fen ^a   Tang, Yue Nian ^a   Jiang, Xin ^c   Lu, Gen Sheng ^b   Zhang, Jian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer risk; FASLG; Genetic polymorphism; Promotor

Indexed keywords

FAS LIGAND;

ARTICLE; ASIAN; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; ETHNICITY; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; LUNG CANCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; UTERINE CERVIX CANCER;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAS LIGAND PROTEIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; ODDS RATIO; POLYMORPHISM, GENETIC; RISK;

EID: 69249105664     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.04.001     Document Type: Article

References (31)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Lutz J.M., Francisci S., Mugno E., Usel M., Pompe-Kirn V., and Coebergh J.W. Cancer prevalence in Central Europe: the EUROPREVAL study. Ann Oncol 14 (2003) 313-322
3. Karim-Kos H.E., De Vries E., Soerjomataram I., Lemmens V., Siesling S., and Coebergh J.W. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44 (2008) 1345-1389
4. Lichtenstein P., Holm N.V., and Verkasalo P.K. Environmental and heritable factors in the causation of cancer. N Engl J Med 343 (2000) 78-85
5. Griffith T.S., and Brunner S. FAS ligand-induced apoptosis as a mechanism of immune privilege. Science 270 (1995) 1189-1192
6. Wu J., Metz C., Xu X., et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promotor alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170 (2003) 132-138
7. Crew K.D., Gammon M.D., Terry M.B., et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 28 (2007) 2548-2551
8. Krippl P., Langsenlehner U., Renner W., Koppel H., and Samonigg H. Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96 (2004) 1478-1479 [author reply 9]
9. Zhang B., Sun T., Xue L., et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 28 (2007) 1067-1073
10. Sun T., Zhou Y., Li H., et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 202 (2005) 967-974
11. Lai H.C., Lin W.Y., Lin Y.W., et al. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol 99 (2005) 113-118
12. Kang S., Dong S.M., Seo S.S., Kim J.W., and Park S.Y. FAS -1377G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet 180 (2008) 1-5
13. Ivansson E.L., Gustavsson I.M., Magnusson J.J., et al. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer 121 (2007) 2451-2457
14. Li C., Wu W., Liu J., et al. Functional polymorphisms in the promotor regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics 16 (2006) 245-251
15. Zhang X., Miao X., Sun T., et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 42 (2005) 479-484
16. Park S.H., Choi J.E., Kim E.J., et al. Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 54 (2006) 303-308
17. Zhang Z., Wang L.E., Sturgis E.M., et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12 (2006) 5596-5602
18. Zhang H., Sun X.F., Synnerstad I., and Rosdahl I. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J 13 (2007) 233-237
19. Li C., Larson D., Zhang Z., et al. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 16 (2006) 253-263
20. Sun T., Miao X., Zhang X., et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96 (2004) 1030-1036
21. Hsu P.I., Lu P.J., Wang E.M., et al. Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions. Anticancer Res 28 (2008) 97-103
22. Ter-Minassian M., Zhai R., and Asomaning K. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 29 (2008) 2147-2152
23. Erdogan M., Karadeniz M., Berdeli A., et al. Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population. J Endocrinol Invest 30 (2007) 411-416
24. Yang M., Sun T., Wang L., et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 14 (2008) 3230-3236
25. Cochran W.G. The combination of estimates from different experiments. Biometrics 10 (1954) 101-129
26. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clini Trials 7 (1986) 177-188
27. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959) 719-748
28. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
29. Qiu LX, et al. FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls. Hum Genet 2009. doi:10.1007/s00439-009-0639-4.
30. Maher S.D., Toomey C., Condron D., and Bouchier H. Activation-induced cell death: the controversial role of FAS and FAS ligand in immune privilege and tumour counterattack. Immunol Cell Biol 80 (2002) 131-137
31. Oconnell J., Osullivan G., Collins J., and Shanahan F. The FAS counterattack: FAS-mediated T cell killing by colon cancer cells expressing FAS ligand. J Exp Med 184 (1996) 1075-1082